Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...

Webcast links will be available on the Investor Relations section of our website. For more information about the events or questions about registration, interested parties should reach out to their ...

Simulations Plus (NASDAQ:SLP) will release its quarterly earnings report on Monday, 2025-12-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Simulations Plus to ...

Simulations Plus SLP is gearing up to announce its quarterly earnings on Monday, 2025-07-14. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Simulations Plus (SLP) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.10 per share a year ago. These ...